Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The second quarter of 2019 will feature major catalysts for the gene therapy onasemnogene abeparvovec (Zolgensma; to be commercialized by Novartis), the opioid conjugate NKTR-181 (developed by Nektar Therapeutics) and the monoclonal antibody (mAb) IFX-1 (developed by InflaRx). Both Zolgensma and NKTR-181 face regulatory approval decisions from the FDA in their respective indications of spinal muscular atrophy (SMA) and chronic lower back pain (CLBP). InflaRx will be reporting top-line results from its phase IIb SHINE study of IFX-1 for the treatment of hidradenitis suppurativa.